We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Colorado Adult Joint Assessment Scale (CAJAS) Validation (CAJAS)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02284789
First Posted: November 6, 2014
Last Update Posted: December 3, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Bayer
  Purpose
To obtain evidence of content validity and reliability of the Colorado Adult Joint Assessment Scale (CAJAS), a clinician-reported outcome (ClinRO) measure, as adapted for use in a population of adults with moderate to severe hemophilia A treated with coagulation factor VIII (FVIII) therapy as secondary prophylaxis or episodic treatment.

Condition Intervention
Hemophilia A Other: Colorado Adult Joint Assessment Evaluation

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Content and Psychometric Validation Study of the Colorado Adult Joint Assessment Scale (CAJAS) in Subjects With Moderate to Severe Hemophilia A Treated on Prophylaxis

Resource links provided by NLM:


Further study details as provided by Bayer:

Primary Outcome Measures:
  • Colorado Adult Joint Assessment Score (CAJAS) [ Time Frame: Up to 25 days ]

Enrollment: 30
Study Start Date: February 2015
Study Completion Date: October 2015
Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
CAJAS evaluation Other: Colorado Adult Joint Assessment Evaluation
Physical evaluation of 6 joints, ankles, knees and elbows

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male, 18 to 50 years of age
  • Diagnosis of moderate to severe hemophilia A (documented <1-2% Factor VIII Concentration [FVIII:C])
  • Willing to maintain current FVIII treatment regimen, whether prophylactic or on-demand, for the duration of the study

Exclusion Criteria:

  • Routine need for wheelchair or routine need for two canes or crutches
  • Diagnosis of another bleeding disorder such as von Willebrand Disease
  • Known event that would interfere with the scheduled CAJAS evaluations (e.g., elective joint surgery, vacation)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02284789


Locations
United States, California
Orange, California, United States, 92868
United States, Colorado
Aurora, Colorado, United States, 80045
United States, Indiana
Indianapolis, Indiana, United States, 46260
United States, Oregon
Portland, Oregon, United States, 97239
Sponsors and Collaborators
Bayer
Investigators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT02284789     History of Changes
Other Study ID Numbers: 17819
First Submitted: November 4, 2014
First Posted: November 6, 2014
Last Update Posted: December 3, 2015
Last Verified: December 2015

Keywords provided by Bayer:
Hemophilia

Additional relevant MeSH terms:
Hemophilia A
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn